Summa Equity has sold its shares in Olink Holding AB (publ) to Thermo Fisher
- News
1 min read

We are pleased to share that Summa Equity has sold its shares in Olink Holding AB (publ) (“Olink”) to Thermo Fisher Scientific Inc. (“Thermo Fisher”) in relation to their announced public cash tender offer of USD 26.00 per common share in cash, representing USD 26.00 per American Depositary Share (ADS) in cash.
Olink, a Summa Equity Fund II investment, develops and markets its unique technology for protein analysis in human protein biomarker research. Through its leading protein detection technology for analysis of human serum Olink has been an important factor in the progress of precision medicine enabling doctors to use the information about a person’s proteins to prevent, diagnose or treat a range of diseases.
For more information, please read the press release here.
For press inquiries please contact:
Hannah Jacobsen, Partner, COO and Head of Investor Relations
hannah.jacobsen@summaequity.com
+47 93 64 19 60
The Summa Summarum newsletter
Sign up to our newsletter
Latest readings
News
Investing in cybersecurity for a secure and resilient digital future
Read more
myneva Group, part of Summa Equity, acquires Kuidado GmbH and strengthens digitalization in social sector
Read more
Summa Equity adds Schulz & Berger to its waste equipment platform to accelerate growth and innovation in circular economy technologies
Read more
The case for scalable regenerative agriculture
Read more
Investing in food and agriculture for health and planetary resilience
Read more